GLOBAL HEALTH & SOCIAL MEDICINE
Dr. Mitnick’s research centers on the improvement of clinical management and programmatic policy for tuberculosis and multidrug-resistant tuberculosis (MDR-TB) globally. Dr. Mitnick is a founding investigator of a movement to conduct randomized controlled clinical trials to improve treatment of drug-resistant TB (RESIST-TB). Dr. Mitnick’s work also includes applying marginal structural modeling to MDR-TB treatment data to assess the effect on outcomes of different types of therapy in observational studies. Dr. Mitnick is the principal investigator of an NIAID grant to plan a Phase II clinical trial examining the potential of high-dose rifampin to shorten standard TB therapy. Her research questions are strongly influenced by the mission of Partners In Health, with which Dr. Mitnick has worked since 1996: she strives to conduct research that will effect changes in global policy to ensure the highest standard of care and best treatment outcomes for patients suffering from all forms of tuberculosis, regardless of where they live.
This influence has also driven Dr. Mitnick’s involvement in global policy efforts. She contributed to the original and revised Guidelines for the Programmatic Management of MDR-TB. She sought, through the publication, Randomized trials to optimize treatment of MDR-TB: the time for action is now (PLoS Medicine, 2007), to generate increased support for controlled examination of anti-mycobacterial agents for the treatment of MDR-TB. Through participation in working groups, sub-groups, and task forces of the STOP-TB Partnership, she has co-authored two articles which define research agendas for MDR-TB (Gupta et al., IJTLD, 2003; Cobelens et al., PLoS Medicine 2008) and one that proposed standardized definitions for analysis of MDR-TB treatment outcomes (Laserson et al., IJTLD, 2005). She consults for the Green Light Committee of the World Health Organization for francophone countries implementing programmatic management of MDR-TB. Her efforts extend to capacity building for recording and reporting on the management of drug-resistant TB, as well as to clinical and operational research in Latin America and beyond. She develops and participates in post-graduate trainings, network-building activities, and trial protocols to be implemented within settings of national TB programs around the world.
Dr. Mitnick graduated cum laude from the University of Rochester in 1988 with a B.A. in political science and French. She spent 1986-1987 in Paris, France, studying at L’Institut d’Etudes Politiques and L’Université de Paris IV. In 1996, she received a masters in international health epidemiology and ecology from the Harvard School of Public Health, and in 2001 she completed a doctor of science degree in international health epidemiology and ecology, also at the Harvard School of Public Health.
The Lancet. Respiratory medicine, April 1, 2018
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, February 1, 2018
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, January 1, 2018
American journal of respiratory and critical care medicine, December 1, 2017
Trials, November 25, 2017
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, October 15, 2017
Antimicrobial agents and chemotherapy, August 24, 2017
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, August 1, 2017
Antimicrobial agents and chemotherapy, July 25, 2017
ERJ open research, July 12, 2017